| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
143,520,000 |
| Market
Cap: |
63.51(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4425 - $0.4425 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile EyePoint Pharmaceuticals is a pharmaceutical company focused on developing and commercializing therapeutics for patients with eye disorders. Co.'s primary product candidate, EYP-19, is a potential sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration. YUTIQ 50 (fluocinolone acetonide intravitreal implant) 0.18 mg for intravitreal injection, is for the treatment of non-infectious uveitis affecting the posterior segment of the eye. DEXYCU® (dexamethasone intraocular suspension) 9%, for intraocular administration, is indicated for the treatment of post-operative ocular inflammation.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1,431,765 |
4,794,057 |
4,794,057 |
4,794,057 |
| Total Buy Value |
$20,571,167 |
$89,496,413 |
$89,496,413 |
$89,496,413 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
2 |
6 |
6 |
6 |
| Total Shares Sold |
0 |
6,161,499 |
6,722,029 |
6,722,029 |
| Total Sell Value |
$0 |
$121,266,413 |
$128,353,600 |
$128,353,600 |
| Total People Sold |
0 |
6 |
7 |
7 |
| Total Sell Transactions |
0 |
24 |
32 |
32 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2023-12-04 |
4 |
S |
$22.00 |
$673,750 |
D/D |
(30,625) |
25,707 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2023-12-04 |
4 |
OE |
$10.13 |
$310,231 |
D/D |
30,625 |
56,332 |
|
- |
|
| Lurker Nancy |
Executive Vice Chair |
• • – |
2023-12-04 |
4 |
S |
$20.76 |
$415,200 |
D/D |
(20,000) |
170,559 |
|
- |
|
| Essex Woodlands Ix, Llc |
See footnotes 1 and 3 |
– – • |
2023-09-01 |
4 |
S |
$9.90 |
$197,982 |
I/I |
(20,000) |
3,490,921 |
|
- |
|
| Essex Woodlands Ix, Llc |
See footnotes 1 and 4 |
– – • |
2023-08-29 |
4 |
S |
$10.74 |
$944,225 |
I/I |
(87,854) |
3,650,392 |
|
- |
|
| Essex Woodlands Ix, Llc |
See footnotes 1 and 4 |
– – • |
2023-08-28 |
4 |
S |
$11.71 |
$712,653 |
I/I |
(60,858) |
3,738,246 |
|
- |
|
| Essex Woodlands Ix, Llc |
See footnotes 1 and 2 |
– – • |
2023-08-25 |
4 |
S |
$10.67 |
$931,479 |
I/I |
(84,656) |
3,799,104 |
|
- |
|
| Essex Woodlands Ix, Llc |
See footnotes 1 and 2 |
– – • |
2023-08-24 |
4 |
S |
$14.62 |
$2,036,093 |
I/I |
(139,280) |
3,883,760 |
|
- |
|
| Essex Woodlands Ix, Llc |
See footnotes 1 and 2 |
– – • |
2023-08-23 |
4 |
S |
$13.05 |
$1,580,915 |
I/I |
(121,103) |
4,023,040 |
|
- |
|
| Essex Woodlands Ix, Llc |
See footnotes 1 and 2 |
– – • |
2023-08-22 |
4 |
S |
$14.62 |
$683,834 |
I/I |
(46,778) |
4,144,143 |
|
- |
|
| Zaderej Karen L. |
|
– • – |
2023-07-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,000 |
2,000 |
|
- |
|
| Adamis Anthony P |
|
– • – |
2023-06-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,000 |
2,000 |
|
- |
|
| Liu Ye |
|
– • – |
2023-05-30 |
4 |
S |
$6.00 |
$6 |
I/I |
(1) |
3,010,721 |
|
- |
|
| Dicicco Wendy F |
|
– • – |
2023-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,000 |
7,400 |
|
- |
|
| Elston George |
Chief Financial Officer |
• – – |
2023-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,800 |
23,116 |
|
- |
|
| Guyer David R |
|
– • – |
2023-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,000 |
7,400 |
|
- |
|
| Landis John B. |
|
– • – |
2023-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,000 |
11,400 |
|
- |
|
| Jones David Scott |
SVP & Chief Commercial Officer |
• – – |
2023-02-09 |
4 |
D |
$4.17 |
$12,327 |
D/D |
(2,956) |
25,133 |
|
- |
|
| Jones David Scott |
SVP & Chief Commercial Officer |
• – – |
2023-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,967 |
28,089 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2023-02-09 |
4 |
D |
$4.17 |
$15,612 |
D/D |
(3,744) |
25,707 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2023-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,800 |
29,451 |
|
- |
|
| Ando Goran |
|
– • – |
2023-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,250 |
8,150 |
|
- |
|
| Duker Jay S. |
President and COO |
• – – |
2023-02-09 |
4 |
D |
$4.17 |
$17,297 |
D/D |
(4,148) |
29,221 |
|
- |
|
| Duker Jay S. |
President and COO |
• – – |
2023-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,967 |
33,369 |
|
- |
|
| Lurker Nancy |
CEO |
• • – |
2023-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
37,533 |
190,559 |
|
- |
|
268 Records found
|
|
Page 4 of 11 |
|
|
